- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 564068 [Title] => Elderly colorectal cancer patients live cancer-free longer [Summary] =>The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
[DatePublished] => 2010-04-08 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 293346 [Title] => Study offers new hope for colon cancer cases [Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.
Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age.
[DatePublished] => 2005-08-25 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 284181 [Title] => Oral chemotherapy: A unique treatment option [Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting.
In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.
[DatePublished] => 2005-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 275629 [Title] => Adjuvant treatment for colon cancer OKd [Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer.
The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment.
Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.
[DatePublished] => 2005-04-28 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
CAPECITABINE
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 703067 [Title] => Roche's drug receives broader EU label for women with metastatic breast cancer [Summary] =>BASEL, Switzerland — Roche announced this week that the European Commission (EC) has extended the existing bevacizumab metastatic breast cancer label to include combination with capecitabine.
[DatePublished] => 2011-07-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 564068 [Title] => Elderly colorectal cancer patients live cancer-free longer [Summary] =>The results of the international phase III study NO16968 (XELOXA), an open-label, randomized trial of Xelox (oral capecitabine in combination with intravenous oxaliplatin) versus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for patients with stage III colon cancer who have undergone surgery, showed the superiority of Xelox versus 5-FU/LV in terms of disease-free survival (DFS).
[DatePublished] => 2010-04-08 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [2] => Array ( [ArticleID] => 293346 [Title] => Study offers new hope for colon cancer cases [Summary] => Colon cancer is a leading cause of cancer deaths in both men and women, occurring most frequently in men and women older than 50.
Colon cancer is most common in people who smoke, eat a high-fat diet, and have a family history of colorectal cancer. However, majority of colon cancers occur in people older than 50 with no known risk factors other than age.
[DatePublished] => 2005-08-25 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 284181 [Title] => Oral chemotherapy: A unique treatment option [Summary] => Recent data further strengthen the wealth of evidence showing that capecitabine, an innovative oral chemotherapy, should replace the current standard treatment of intravenous 5-fluorouracil/leucovorin (i.v. 5-FU/LV) for colon cancer patients in the adjuvant (post-surgery) setting.
In March 2005, Roche received approval from European authorities for capecitabine to be used as a post-surgery treatment in colon cancer patients.
[DatePublished] => 2005-06-30 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [4] => Array ( [ArticleID] => 275629 [Title] => Adjuvant treatment for colon cancer OKd [Summary] => European authorities recently approved capecitabine, an innovative oral chemotherapy, as an adjuvant treatment (post-surgery) for colon cancer.
The drug has been shown to prolong cancer-free survival with less serious side effects compared to standard current treatment.
Adjuvant chemotherapy is a standard treatment approach for stage III colon cancer to destroy cancer cells remaining in the body after the tumor has been surgically removed.
[DatePublished] => 2005-04-28 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
EZ2 - 11 28
SUERTRES - 3 0 8
6D Lotto - 9 4 2 1 6 7
6/42 Lotto - 28 19 35 41 25 3
P19,593,195.00
6/49 Super Lotto - 16 41 26 27 44 21
P15,840,000.00
- 12:00 am